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Abstract
Background: Hematopoietic stem cell transplants, alongside enzyme replacement therapy and good multi-disciplinary
care, have dramatically improved the life expectancy in children with Mucopolysaccharidosis (MPS) I, with better
objective and functional outcomes. Despite these improvements, children with both the attenuated (non-Hurler)
and severe (Hurler) variants of the disease have marked residual morbidity. Children with MPS I suffer with head
and neck disease including obstructive sleep apnoea and hearing loss. The impact of these on quality of life has
been poorly researched and no previous work has been published looking at patients’ perception of their own
health, an important domain when considering the impact of treatment.
Methods: This exploratory qualitative study aimed to discover the effect of head and neck disease, alongside that
of MPS I as a whole, on the quality of life of affected children.
A grounded theory approach was used to conduct this study. Children and their parents were invited to participate in
semi-structured interviews. The transcribed interviews were coded and emergent themes explored until saturation
occurred.
Results: The families of eleven children with MPS I were interviewed, five with Hurler’s and six with the attenuated
non-Hurler’s. Important themes to emerge were- the fear of dying associated with obstructive sleep apnoea, difficulties
communicating at school due to the delayed acquisition of language, chronic pain and restricted mobility, physical
differences and restricted participation in social activities such as sports secondary to the musculoskeletal disease
burden. The overall theme running through the analysis was the desire to fit in with ones peers.
Conclusion: Parents and children with MPS 1 worry about ‘fitting-in’ with broader society. The presence of airway
disease has a profound impact on the emotional well being of parents whilst language delay and musculoskeletal
disease have the biggest impact on the quality of life of the children themselves. It is important to understand the
impact of MPS I on the quality of life of children and their families so that we may improve future treatment and
management of this sub-group of children who have an increasing life span.
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Background
Mucopolysaccharidosis type I (MPS I) is an autosomal
recessive disorder secondary to a deficiency of the en-
zyme, α1-iduronidase [1–3]. α1-iduronidase, is involved
in the degradation of the glycosaminoglycan’s (GAG’s)
and a deficiency of the enzyme results in a build up of
GAG’s within tissues [1]. How accumulation of these
GAG’s leads to clinical symptoms is poorly understood
[4]. The mutational variability described produces vast
clinical phenotypic heterogeneity giving rise to a disease
spectrum ranging from the severe (Hurler’s) form, which
is characterized by early development of progressive cen-
tral nervous system (CNS) disease, to the attenuated
(Non-Hurler’s) form with CNS sparing [5]. Hurler’s, with
its early onset and rapidly progressive symptoms, ac-
counts for seventy percent of children seen with MPS I,
with death occurring within the first two decades if left
untreated [3, 6]. Although children with Non-Hurler’s
have an attenuated form of the disease with slower pro-
gression, they still incur significant morbidity [3]. Head
and neck disease is frequently seen in children with
MPS I, with seventy percent of children suffering multi-
level airway obstruction and moderate levels of hearing
loss (mean threshold 34 dB) [7, 8].
Hematopoietic stem cell transplantation (HSCT) has
become the standard of care for children with Hurler’s;
with early transplantation providing improved clinical
and functional outcomes, including neurodevelopmental,
and a longer life expectancy. The short-term mortality
and longer-term morbidity from the HSCT limits its use
to children with Hurler’s [9–11], whilst those with non-
Hurler’s continue to be managed with enzyme replace-
ment therapy (ERT) [12]. However, with transplant
survival rates now in excess of ninety percent, we may
see this treatment extended on a case-by-case basis to
children with Non-Hurler’s displaying a more severe
genotype and phenotype [13]. We have adopted this
practice in our unit.
Despite the positive impact of disease modifying treat-
ments on life expectancy, these children are growing
older with a substantial burden of residual disease and
understanding the challenges that they face in their daily
lives is becoming increasingly important. To date, no re-
search has been published, which examines the impact
of head and neck disease, or indeed MPS I as a whole,
on the quality of life (QOL) of these children or their
parents. No previous exploratory work has been done
looking at patient’s perception of their own health [14],
an important domain when considering the impact of
invasive treatments. At present no disease specific
tools exist which allow us to assess the impact of MPS
I on QOL.
The aim of this qualitative study, using patient inter-
views, was to explore in-depth the concerns of children
with MPS I and their parents, with an emphasis on the
impact of head and neck disease on their lives. Through
this work, we aim to provide health care professionals
with better insight into the patient’s perception of their
own health and the priorities that they place on different
aspects of their illness. This study also aims to identify
important domains for inclusion in an outcome tool de-
signed to measure disease specific impact on quality of
life in this sub-group of patients.
Method
A grounded theory approach was used to obtain an in-
depth understanding of the impact of MPS I on the lives
of the children and their families. Grounded theory is a
qualitative method of narrative research, which allows us
to explore the lived-in experience of MPS in greater de-
tail than that offered by subjective questionnaires. In
contrast to other narrative methods of research such as
phenomology, it can facilitate the generation of theory,
rooted in the data, which may help explain why certain
aspects of the disease have an impact on QOL [15].
We prospectively recruited eleven patients with MPS I
from a large, internationally renowned, tertiary, pediatric
metabolic medicine and genetics unit between December
2013 and November 2014.
MPS I represents a heterogeneous group of patients
with varying phenotype and severity and therefore pur-
posive sampling was used to include representation of
varied forms of the condition. Children were sixteen
years or under at the time of interview. National Re-
search and Ethics Committee review was obtained prior
to commencement of the study. Informed consent, and
assent for those under the age of sixteen, was obtained
from all study participants, prior to their participation.
Data was generated using semi-structured interviews.
Interviews were conducted when families attended
planned appointments or treatments at the unit. An
open, conversational style was adopted for the inter-
views. The researcher sat in a circle of chairs alongside
the parents and children, allowing face-to-face conversa-
tion. The children were invited to have interviews inde-
pendently to their parents, allowing their views to be
given equal importance. Alternatively they could attend
the interviews with the parents if they preferred. In-
formed consent or assent for those under the age of six-
teen was obtained before the interview was conducted.
Each interview lasted about an hour and was digitally
audio-recorded.
Data collection and analysis were based on the con-
structivist principles of grounded theory, as described by
Charmaz 2006 [16]. We developed a ‘topic guide’ to
steer the interviews. The subjects for inclusion were
guided by clinical experience because no other qualita-
tive studies exist exploring the lives of families living
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with MPS I. Topics related to head and neck disease
were raised in the interview but rather than specifically
privileging these issues, interviewees were encouraged to
discuss them within their overall experience of living
with MPS. As the interviews were semi-structured and
informal, the interviewer asked broad open-ended ques-
tions, allowing the interviewees to steer the interview in
a direction important for them. The interviewer used
probing question to explore responses given by the
interviewees.
In keeping with the inductive principles of grounded
theory the topic guide developed with time, guided by
emerging themes and subjects that appeared to be im-
portant to the families. The initial interviews focused on
the head and neck disease and the impact it may have
on a normal day in the child’s life. Parents were asked to
describe ‘a typical day in their child’s life’. However, it
soon emerged that parents wanted to discuss the topics
‘education’, ‘language’, ‘mobility’, ‘pain’ and ‘sleep apnoea’
in further detail. Hence, subsequent interviews took on a
different format and parents were asked to describe the
main impact of their child’s disease on their lives, includ-
ing education, social integration and future independ-
ence. Parents were allowed to determine the direction of
the interviews and discuss topics important to them.
As the analysis developed, ‘negative’ (i.e. inconsistent)
as well as consistent cases were sought and emergent
themes were adapted to account for variations, in line
with the aim of saturation of categories in grounded
theory [16].
A third party transcribed the interviews verbatim. Each
transcript was then read to determine emerging themes,
guiding further data collection. Field notes were dictated
following each interview to make note of the inter-
viewer’s thoughts and impressions. The transcripts were
entered and analysed using the Qualitative software
NVIVO for Mac© (http://www.qsrinternational.com).
Data analysis was conducted concurrently with data
collection. The first stage was open line-by-line coding
of the primary data. The emergent codes were grouped
into early conceptual categories and through a process
of constant comparison grouped further into larger,
over-arching categories or themes. Emergent themes
were discussed with supervisors as part of a cycle of
reviewing the interpretation of data and exploring emer-
gent themes in subsequent interviews. Hence, the identifi-
cation of categories was iterative, occurring over multiple,
progressive cycles of interview-analysis-open coding and
reflection. We checked for consistency across cases,
searching for negative cases and adapting the categories to
account for variation.
This iterative, cyclical, reflective process allowed the
theory to be developed inductively from the data. Data
were analysed at each stage and further data collection
guided by emergent themes. The final data categories
were linked in a narrative that accounted for the varia-
tions across the sample.
Results
Over the eleven-month period, nineteen children with
MPS I were due to attend the unit for review or treat-
ment on the designated research days and agreed to par-
ticipate in the study. Eight of them did not attend their
designated appointment with the researcher and hence
eleven patients were interviewed.
Seven children were female and four were male. Six
children (one male and three female) had an attenuated
(Non-Hurler) variant of the disease whilst the remaining
five children had the more severe (Hurler) form of the
disease. The age range interviewed was 6 months to
16 years, mean age 7 years. Two of the children had re-
cently been diagnosed with the illness and were aged
6 months and 18 months respectively. Both of them
were female and had Hurler’s syndrome. Both had been
started on ERT on diagnosis and were awaiting HSCT at
the time of interview. This age range interviewed was
important in providing an accurate developmental story
covering the journey from initial diagnosis to the age of
sixteen, highlighting issues that each group may face.
Within the Hurler group (n = 5), the two aforemen-
tioned children were awaiting HSCT, two children were
post-transplant (5 & 10 years) and one was on long-term
ERT (age 16 years). Within the attenuated Non-Hurler
(n = 6) group, four children were on long-term ERT (12,
12, 15 and 15 years) and two children were post-HSCT
(age 18 months and 2.5 years). Both of the transplanted
non-Hurlers were diagnosed in the pre-natal period, as
they had older affected siblings. Both families opted for
their second child to undergo a transplant, rather than
be managed on ERT alone.
Three children with Hurler’s were in a special needs
educational facility. They all suffered with pronounced
developmental delay and varying degrees of neurocogni-
tive disease. Four of the Non-Hurler’s children attended
mainstream school, of which two had mild learning diffi-
culties. Four children (2 Hurler and 2 non-Hurler) were
under the age of five at the time of interview and did
not attend a full-time educational facility.
All children declined the offer to be interviewed separ-
ately to their parents. The older children in our cohort par-
ticipated in the group interviews alongside their parents.
The younger children simply observed the interviews.
Pseudonyms have been given to the children to protect
their identities.
Breathing concerns & nocturnal breath holding
A major source of parental concern was the develop-
ment of obstructive sleep apnoea (OSA) in their children
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at a very young age. Most of the children had developed
it by the age of one year, with some displaying symptoms
as early as three to four months old.
Milo’s mother (age 5), ‘At three months old he devel-
oped loud snoring, which was audible over the television
downstairs. This progressed to breath holding. No one
really thought he could be suffering with sleep apnoea at
this young age.’
In many of the children it appears to have been the
first cause of concern to parents. This was a fearful time
for parents, as many could see that there child was not
breathing properly. Some took to sleeping with their
child at night so that they could closely monitor them.
Milo’s mother (age 5), ‘It used to be a leap of faith put-
ting him to bed. You’d put him to bed and go, god is he
going to be there in the morning? It was horrible. I used
to sleep with him upright on my shoulder as this stopped
him holding his breath as much.’
Ramona’s mother (age 18 months), ‘She wakes up at
least every hour and holds her breath while sleeping. I’ve
been sleeping close to her since I’ve had her. I’ve tried to
put her in a cot, but it just doesn’t work. It stresses her
out’.
The enzyme replacement therapy had a positive im-
pact on the symptoms. Within the first few weeks of be-
ing commenced on the ERT treatment, the snoring and
breath holding had improved and eventually ceased in
most children. Those children with more severe MPS I
had undergone an HSCT, which may have contributed
to the longevity of improvement.
Milo’s mother (age 5), ‘He had the chemotherapy,
followed by the HSCT, and within three months, the se-
vere snoring and breath holding stopped. We are now
four years since completion of the transplant and he has
not suffered since.’
The children reported that the disrupted sleep second-
ary to the OSA made them very tired in the morning, af-
fecting their performance in school.
Mallika’s father (age 15), ‘She used to have symptoms of
heavy breathing, to the point where she stopped breath-
ing for a second or two every night. It did not get better
with the ERT. A few months ago she had an operation
where they removed her tonsils and it has made a huge
difference. The symptoms at night have all gone away
and she is so much brighter in the mornings.’
Three children in our cohort were diagnosed with
MPS very early (two in the pre-natal period and one at
the age of six months prior to the onset of outward
symptoms of OSA). All three were started on ERT on
diagnosis and then offered a hematopoietic stem cell
transplant by the age of six-nine months. To date, these
three children remain free of clinical signs of disease
(oldest child in this cohort is age three years). However,
the improvement in symptoms was not sustained in
children with non-Hurlers who had had a late diagnosis
(>5 years of age) of MPS. They continued to suffer with
progressive disease, requiring a surgery in their early
teens, which participants reported led to sustained im-
provement in their symptoms.
One child in our cohort, Adam (age 16) with Hurler’s
has severe multi-level upper airway disease. His upper
airway disease and its impact on his life seemed more
profound than the other children in our study. His snor-
ing and obstructive sleep apnoea have progressively
worsened with increasing age, and at the age of 16, he
had been admitted to hospital multiple times requiring
oxygen and pressure ventilation support, having to re-
main in hospital for a week at a time. He also required a
continuous positive airway pressure (CPAP) machine at
home to support his breathing at night. His parents are
now scared that he may completely stop breathing one
night and hence vigilantly monitor him whilst at home.
They are reluctant to take holidays far from his main
hospital, should this happen suddenly. They also worry
about him having general aneasthetics. However, they
are very accepting of the need for the CPAP machine at
home as they feel it improves his quality of life and also
his life span.
Thus breathing was a major source of concern from
infancy, with improvements in symptoms after commen-
cing ERT and HSCT in all children. However, improve-
ments in breathing were not sustained for children with
non-Hurlers who commenced treatment later than five
years old.
The acquisition and development of spoken language
Children with attenuated Non-Hurlers and their parents
did not report any concerns with regards to language
and hearing. However, parents of children with Hurlers,
raised concerns over their children’s delayed acquisition
of language, in comparison with their peers and siblings.
These children had language delay, with many of them
not reaching their early speech milestones, with no dis-
cernable language at diagnosis of the illness. Parents felt
that this delay was due to a number of factors, including
physical changes in their child such as a large tongue,
poor hearing or developmental delay due to neurocogni-
tive disease.
Ramona’s mother (age 18 months), ‘during her newborn
hearing screening they could not get a consistent reading
and diagnosed her with hearing loss. We didn’t know at the
time that she had MPS. She was wearing two hearing aids
by three months of age. Despite the hearing aids, she could
not say any words at all until the ERT was started four
weeks ago. It was difficult for her and she used to be quite
clingy, with me having to carry her everywhere. Since the
treatment, she is making sounds like ‘dada’ and the other
day actually said ‘book’. It was such a special moment.’
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Parents commented that the ERT rapidly improved
the speech with children speaking within weeks of it be-
ing started, much to the amazement of their parents.
Those parents with multiple children commented that
although the speech markedly improved with the treat-
ment, it was never as good as the children’s other non-
affected siblings or peers at school and the mild speech
impediment and delayed grammar, carried through into
secondary school. Two parents, with multiple affected
children, felt that the children treated with HSCT had
better language than the children treated with ERT
alone, but was still delayed and lacking in clarity, in
comparison with unaffected children.
Milo’s mother (age 5), ‘He was nearly three years old
before you could make anything legible out when he
spoke. It was predominantly babbling and noises. It has
slowly improved and he has progressed to full conversa-
tional sentences. However, It is not where a five year old
child should be.’
Mallika’s father (age 15), ‘She still has a delay in her
language even at fifteen, she gets stuck with some words
and there are others that she simply can’t pronounce.
Sometimes she gets embarrassed or cross about this.’
Some parents felt that the language delay was in part
due to their child’s underlying hearing loss. Parents de-
scribed children having a very positive relationship with
their hearing aids. The younger ones consistently asked
to wear them whilst the older children felt that they
helped them hear everything in their social environment,
both at home and at school, allowing them to achieve an
education and communicate effectively with others.
Ramona’s mother (age 18 months), ‘She points to them
if they are not in. She gets frustrated with me if I don’t
put them straight in.’
Parents described hearing aids providing a vital lifeline
to the outside world, especially for the younger children.
The importance of hearing for parents was indicated by
their expressions of frustration about the apparent low
priority given to their audiology appointments by other
health care staff, with these being frequently cancelled if
they coincided with other hospital appointments.
Ramona’s mother (age 18 months), ‘She has outgrown
her left hearing aid and is completely deaf on that side.
We have to rely on just the one working aid. The hearing
aid appointment has had to be cancelled twice to make
time to come to the hospital for the ERT.’
Older children got angry when they could not hear in
a noisy environment or localize sound effectively. They
also got cross when siblings or other children would not
repeat things for their benefit. They expressed feeling
confused in a noisy or busy environment, as the sound
was not clear. Some said their confidence was affected
when trying to express themselves or communicate with
teachers and peers at school.
In summary, hearing difficulties had important conse-
quences for the lives of children, affecting their ability to
communicate and their education, which was a major
concern for parents of affected children.
Musculoskeletal disease, mobility and independence
For many parents and children, pain and stiffness within
the muscles and joints, alongside the outward physical
appearance of these musculoskeletal manifestations, had
a large impact on their children’s quality of life.
Musculoskeletal disease started in infancy, with most
children developing curvature of their spine, seen as a
lump in the back, or trigger fingers and toes. In many
these had led to the diagnosis of the disease. It had also
contributed to delayed physical milestones such as
crawling and walking and many children were still not
mobile into their second year of life. The initiation of
weekly enzyme infusions rapidly improved the child’s
mobility and energy levels allowing them to catch up
with other toddlers their age.
Amanda’s mother (age 12), ‘within seven days of ERT
suddenly she was running around the house…she somer-
saulted off the back of the sofa. She had never done that
in her life ever. She was four and a half.’
Ramona’s mother (age 18 months), ‘we started the ERT
four weeks ago and she has now started walking. Before we
came here she couldn’t crawl or stand up on her own.’
Neither ERT nor HSCT were reported to stop or re-
verse the disease process completely and musculoskel-
etal problems continued to develop as the children grew.
In our study even those with the most attenuated form
of the disease still had significant disease burden. This
had an impact on children’s ability to participate in the
most basic activities such as sitting up when laid down,
climbing a flight of stairs and walking, perhaps to school.
The persistent curvature in their spine stopped them
standing straight and they had stiffness in their joints,
from their fingers and wrists to their shoulders, neck
and lower limbs. This stiffness was also accompanied by
pain, brought on by use, in some cases even after ten
minutes of walking or writing. Many had developed
clawing of their hands.
Ayesha (age 15), ‘I get pain in my legs when I walk to
school in the morning. I stop for a few minutes and then
start again slowly. Sometimes I lose my balance and fall
over.’
Amanda’s mother (age 15), ‘Even now, from a lying pos-
ition she can’t sit up. I have to help her. The walking is
an even bigger concern for us.’
Children with non-Hurlers were able to attend main-
stream school. Climbing up and down stairs was challen-
ging and time consuming and hence for their own safety
they left the lesson five minutes earlier than the other
children and used the stairs or lift to travel up and
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down. They had multiple sets of schoolbooks, one at
home and one at school to save them carrying a heavy
bag. Some of them had a teaching assistant to write for
them or to carry their books and bags for them.
Ayesha (age 15), ‘at school, I have a helper to carry my
bag and books between my classes. It means that I don’t
get as tired and it stops my shoulders and back from
hurting.’
Amanda (age 12), ‘I don’t want a classroom assistant. I
think it will make me less independent and attract atten-
tion. It would be helpful with my writing but I manage
by just shaking my hands whilst writing to get rid of the
cramp. My friends help with my bag and I take the lift
instead of the stairs.’
Older children, from the age of eight onwards, found
it frustrating that they could not participate in sports or
run like their friends. Or if they could manage it, they
had to adopt a different technique to accommodate the
stiffness and the disability.
Andrew (age 12), ‘I play cricket at school but I can’t
raise my arm above my shoulder to bowl and so have
had to change the way I bowl. I can’t really play football,
as you need to be able to run faster than in cricket to get
the ball and I can’t manage that. When I play cricket I
find the extra weight of the shin pads difficult to carry.’
Amanda (age 12), ‘I get annoyed at not being able to
participate in sports or run. I get tired very easily. I can-
not stand properly and walking hurts my back and my
feet if it is for longer than ten minutes.
Children of the same age had also become self-aware
and realised that their physical appearance and physical
stamina were both different to other children around
them. Teenage girls kept a low profile at school and
avoided changing in front of their peers in the changing
rooms. They felt sad missing out on social activities such
as going shopping with friends, as their restricted mobil-
ity would mean the need for a wheelchair, causing them
further embarrassment.
Amanda (age 12), ‘I don’t want to be different, so I just
try to blend in and I don’t tell anybody about my condi-
tion.’ ‘I don’t like the way my tummy is swollen and looks
so big. Also, the way I stand and walk looks funny. My
fingers stick out, people might look at them.’
This idea of difference from ones peers, despite severe
musculoskeletal disability, was not an issue for children
who had affected siblings and cousins with MPS I. Per-
haps having other children in your immediate surround-
ing with similar problems normalises the problem,
allowing the child to attain a shared identity.
All of the children in our group, including those with
an attenuated form of the disease, relied on wheelchairs
if they had to walk more than ten-twenty minutes at a
single stretch. Parents described children as accepting of
the wheelchairs and some felt the children were
sometime too easily ready to sit in them and not exert-
ing themselves to their full physical ability. However,
Amanda (age 12) did comment that she did not want to
use the wheelchair in front of her peers as it made her
stand out, highlighting her difference to them. The inter-
views highlighted that wheelchair use within a main-
stream school facility could be difficult and the children
preferred to walk around for the day, albeit with assist-
ance or slowly.
Three children with Hurler’s required a special needs
education, primarily due to autism or severe learning
difficulties. From a musculoskeletal point of view, the
big advantage of the specialist schools was that they
were on one level and the children could easily use their
wheelchairs to get around if necessary. They also offered
allied services such as physiotherapy and access to a
hydrotherapy pool.
Most parents worried about their child’s future physical
health, with some voicing concerns about the children
growing into adults who were wheelchair bound, unable
to live independently, perhaps becoming institutionalised.
Milo’s mother (age 5), ‘we worry most about his inde-
pendence, whether he's going to be stuck with his old
mum for the rest of his life. I want him, you do for your
children, to be educated, independent, working, house,
family, just happy, doing the normal, run of the mill
things. I wouldn't want to see him in care homes and
institutions.’
It was therefore apparent that children emphasised
how mobility problems could highlight their difference
to their peers, for example by limiting their involvement
in activities. Parents were also concerned about the im-
plications for children’s adult lives.
The emotional impact of the disease
Participants said that young children, 5–6 years had de-
veloped awareness of their condition and their difference
to other children around them. As they grew older their
awareness increased and girls in particular were con-
scious of their physical appearance and having less phys-
ical stamina than peers. Their parents suggested many
had developed shy, introverted personalities when not in
their home environment.
Amanda’s mother (age 12), ‘She has a tremendous per-
sonality at home but becomes painfully shy when we go
out. I’m worried that academically she will be a high
achiever but will be an emotional wreck by the time she is
in her twenties, burdened down by anxiety and depression.’
Young people’s wish to minimise their difference was
illustrated by a fifteen-year-old girl (Ayesha) who stated
during the interview that she did not feel different to her
peers and that her physical appearance and severe mus-
culoskeletal disabilities were not a problem for her.
However, her mother contradicted this by saying that
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she was always angry at home, shouting at her mother
and siblings and if very frustrated, would resort to delib-
erate self-harm.
Some parents expressed relief at their child looking
outwardly normal and not suffering from intellectual im-
pairment. For them, the mental and physical disabilities
that may be linked to the condition were hard to cope
with. They expressed the desire for their children to be
similar to their peers and fit-in with society at large. One
mother said that when she was first informed of her
child’s illness, she was shown pictures of children with
the severe form of the disease. For her this was the scari-
est part of the diagnosis and she left the hospital ap-
pointment that day feeling horrified. They saw HSCT as
an opportunity for their children to live a more normal
life.
Maya’s father (age 6 months), ‘the worst nightmare for
a parent is that you have an unhealthy or a disabled
child. There is no option for us than to go ahead with the
bone marrow transplant. It can give her a normal life.’
Time off school for treatments and hospital appoint-
ments was a concern for parents due to the burden of
catching up on missed classes and homework. Many
children required extra tuition or quite heavy parental
support and encouragement to stop them falling behind
at school.
Ayesha’s mother (age 15), ‘Despite the tuition classes,
she does not achieve the same grades as her cousins. I
am worried that without an education she will not have
an independent future after we die.’
Discussion
Summary of findings
Participants highlighted effects on breathing, hearing
and mobility when they described living with MPS.
These problems were associated with emotional effects
and could have major impact on children’s social lives.
The presence of multi-level airway disease and second-
ary obstructive sleep apnoea was a major source of con-
cern for the parents of children with MPS I, with many
voicing fears about their child dying as a direct result of
this. Parents reported that the obstructive symptoms
started as early as three-six months of age, prior to the
diagnosis of MPS being established, earlier than the age
of two reported in the literature [17, 18]. Seventy-five
percent (n = 8) of children in our study had suffered with
it at some stage of their illness, in keeping with the pub-
lished literature [19].
Parents of children treated early with ERT and HSCT
reported marked and sustained improvement in chil-
dren’s airway symptoms, with many of them reporting
resolution of symptoms after HSCT. Parents of those
with non-Hurler’s diagnosed later than 5 years of age, or
treated with ERT alone, described minimal improvement
in their symptoms, requiring an adenotonsillectomy in
adolescence. These reports from a small sample of par-
ental observations are consistent with the findings of a
published multi-variant analysis which show that early
transplantation in Hurlers and early ERT in non-Hurlers
provide the most sustained improvements in airway dis-
ease [20].
Participants’ accounts of the effects on their lives ap-
peared related to the severity of MPS I. Those with
children with attenuated phenotypes reported limited
impact on breathing, hearing or mobility into adoles-
cence whilst those with more severe Hurler’s phenotypes
described life limiting airway disease, including both
CPAP and oxygen dependence in their late teens. These
accounts from a small sample are consistent with the lit-
erature which confirms that the severity of the OSA
worsens with age, with poorer polysomnography scores
seen in post-pubescent patients [21].
The impact on breathing in infancy and early child-
hood was primarily on the parents, who described be-
coming stressed and worried about their child’s inability
to breathe at night and the fear that they may die. They
also described being exhausted from being awake with
their child every night and co-sharing their bed at night.
Parents described improvements to their stress and sleep
following HSCT, which improved children’s symptoms.
Breathing problems can also be tiring for children: ado-
lescents with persistent airway obstruction report feeling
exhausted in the morning with consequences for their
performance at school.
The central theme of the accounts of parents and chil-
dren alike was that they wanted to achieve social inte-
gration and acceptance and ‘fit-in’ with peers. Problems
with acquisition of language and mobility were import-
ant influences on children’s ability to ‘fit-in’ with peers.
Delayed language appeared to be problematic for all of
the children but parents described rapid improvement
following ERT treatment. A few children had an under-
lying hearing loss but despite adequate early rehabilita-
tion of this, parents said that their language acquisition
and clarity did not improve until initiation of ERT.
Those receiving HSCT in addition to ERT described the
greatest improvement. However, participants noticed
that a mild degree of language delay and loss of speech
clarity persisted even into adolescence.
Participants’ accounts suggest that musculoskeletal
disease has a very big impact on the children’s lives. The
literature describes that musculoskeletal abnormalities
associated with MPS [5, 22], measured using functional
outcomes, improves over time with ERT [23]. However,
no previous reports of the impact of musculoskeletal
disease on the children’s lives have been published. Our
study shows that despite ERT, the children continue with
a marked burden of musculoskeletal disease, which
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interferes with the child’s ability to fit in with their peers.
This is due to their altered physical appearance, the need
for adjuncts such as wheelchairs and being excluded
from group activities such as team sports or shopping
trips. The physical disability is also responsible for feel-
ings of inadequacy, loss of self-confidence, anger and de-
pression. Parents worry that it may also lead to loss of
independence and the inability to seek employment, des-
pite good educational achievement.
With advances in medical therapy, primarily ERT
and HSCT, these children are living longer, healthier
lives. It is important to understand the impact of the
disease on the quality of life of the children and their
parents, allowing future treatment decisions to be rele-
vant and appropriate to their specific needs. This ex-
ploratory work also highlights important themes,
which could contribute to the development of a future
patient reported outcome measure that may be used to
assess health related quality of life in children with
MPS 1.
Strengths and limitations
To our knowledge, this is the first study of its kind to
explore in-depth the perception of parents and children
on the impact of head and neck disease on the QOL of
children with MPS I and their parents.
This is the first study to report the impact of airway
obstruction on children with MPS I and their carers. Ex-
tensive research has previously explored the impact of
OSA on otherwise healthy children. They show that
those with OSA have a significantly poorer quality of
life, mainly in the areas of general health perception and
emotional parental impact. Other subsets affected are
bodily pain, physical functioning and family activities.
They also score worse than children with Juvenile
Rheumatoid Arthritis (JRA) and asthma, significantly in
the subsets parental impact-time and parental-impact
emotional, with some impact on behavior and social lim-
itations. Lack of parental sleep and constant worry about
the health of the young child may be a source of stress
for many parents of children with OSA [24–27]. The
broader literature also reveals that fragmented sleep and
recurrent hypoxia induced arousals in younger children
may cause symptoms of hyperactivity, inattention, poor
concentration, disruptive behavior such as fighting,
bullying and being quarrelsome, labile emotional behav-
ior and poor school performance [28, 29]. Along with
behavioral disturbance, studies have reported cognitive
impairment with a reduction in intelligence quotient
scores and working memory [30]. Working memory is
essential for problem solving and normal psychological
development in children. In the older adolescents OSA
may cause hyper somnolence in the day, poor concen-
tration and lead to depression [29].
These results are based on parental interviews and
provide preliminary data. This would have to be further
quantified, in future research studies, using both subject-
ive and objective outcome measures post-transplant,
alongside long-term observational studies to see if this im-
provement is sustained into adulthood. Published clinical
trials assessing the benefit of ERT on MPS I report a re-
duction in the apnea-hypopnea index on serial overnight
sleep studies after treatment with ERT is commenced but
do not use subjective outcomes measures to quantify the
perceived improvement in quality of life [12, 31, 32].
Many important categories have emerged and contrib-
uted to our understanding of children and parents’ ex-
perience of living with MPS I. Although we drew on the
principles and procedures of grounded theory method-
ology, we have identified insights into experience rather
than developed a full-grounded theory. Although the
children were participants in the interviews, the princi-
pal data source is parents’ accounts and we must be
aware that parents and children’s accounts of living with
chronic diseases can differ, particularly as they relate to
emotional and social well being [33].
Conclusion
Parents and children with MPS 1 worry about ‘fitting-in’
with broader society and their peers. The presence of
airway disease in the children has a profound impact on
the emotional well being of parents whilst language
delay and musculoskeletal disease have the biggest im-
pact on the quality of life of the children themselves. It
is important to understand the impact of MPS I on the
quality of life of children and their families so that we
may improve future treatment and management of this
sub-group of children with an increasing life span.
Abbreviations
CNS, Central nervous system; CPAP, Continuous positive airway pressure; ERT,
Enzyme replacement therapy; GAG’s, Glycosaminoglycan’s; HSCT, Hematopoietic
stem cell transplantation; JRA, Juvenile Rheumatoid Arthritis; MPS I,





No internal or external funding was received for this research study.
Availability of data and materials
The dataset supporting the conclusions of this article are included within the
article itself.
Authors’ contributions
ASJ designed, collected and analysed the data as part of an MPhil degree.
She performed the literature search and wrote the paper. IAB and PC were
her academic supervisors and were involved in the design and conception
of the study. They also closely supervised and reflected on all stages of data
collection and analysis. JM assisted in patient recruitment. SAJ reviewed and
edited the paper. All authors take full responsibly for the contents of this
paper and act as guarantors.
Soni-Jaiswal et al. Orphanet Journal of Rare Diseases  (2016) 11:96 Page 8 of 9
Authors information
Professor Peter Callery is a professor at the University of Manchester, England,
and has an interest in Qualitative research, primarily looking at quality of life in
children. He has authored over a hundred papers in qualitative research and
has been awarded many national grants to facilitate this.
Dr. Archana Soni-Jaiswal undertook this project as part of a post-graduate
research degree at the University of Manchester, England, under the supervision
of Professors Peter Callery and Iain Bruce.
Competing interests
All authors declare no competing interests. No external or internal funding
was received for this work.
Consent for publication
Not applicable.
Ethics approval to consent to participate
National Research and Ethics Committee review (Edgbaston Research and
Ethics Committee, reference number 13/WM/0391, England) was obtained
prior to commencement of the study. Informed consent, and assent for
those under the age of sixteen, was obtained from all study participants,
prior to their participation.
Author details
1Respiratory and Allergy Centre, Institute of Inflammation and Repair, Faculty
of Medical and Human Sciences, University of Manchester, Manchester M13
9PL, UK. 2Willink Unit, Saint Mary’s Hospital, Central Manchester University
Hospitals NHS Foundation Trust, Manchester M13 9WL, UK. 3Paediatric ENT
Department, Royal Manchester Children’s Hospital, Central Manchester
University Hospitals NHS Foundation Trust, Manchester Academic Health
Science Centre, Manchester M13 9WL, UK. 4School of Nursing, Midwifery and
Social work, University of Manchester, Manchester M13 9PL, UK.
Received: 27 January 2016 Accepted: 27 June 2016
References
1. Neufield EF, Muenzer J. The mucopolysachharidoses. In: Scriver CBA, Sly W,
editors. The metabolic and molecular bases of inherited disease. New York:
N: McGraw Hill; 2001. p. 3421–52.
2. Meikle PJHJ, Clague AE, Carey WF. Prevalence of lysosomal storage
disorders. JAMA. 1999;281(3):249–54.
3. Moore D, Connock MJ, Wraith E, Lavery C. The prevalence of and survival in
Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the
UK. Orphanet J Rare Dis. 2008;3:24.
4. Muenzer JWJ, Clarke LA. International Consensus Panel on, Management
Treatment of Mucopolysaccharidosis, I. Mucopolysaccharidosis I:
management and treatment guidelines. Pediatrics. 2009;123(1):19–29.
5. Muenzer JB, Eng C, Giugliani R, Harmetz P, Martin R, Ramaswami U, Vellodi
A, et al. Overview of the mucopolysaccharidoses. Rheumatology (Oxford).
2011;50 Suppl 5:v4–12.
6. Scott HSBS, Gal A, Clark LA, Morris CP, Hopewood JJ. Molecular genetics of
mucopolysaccharidosis type I: diagnostic, clinical and biological
implications. Hum Mutat. 1995;6(4):288–302.
7. Moreira GV, Kyosen SO, Patti CL, Martins AM, Tufik S. Prevalence of
obstrucive sleep apnoea in patients with mucopolysaccharidosis type I, II
and VI in a reference centre. Sleep Breath. 2014;18:791–7.
8. Lin H, Shih S, Chuang C, Lee K, Chen M, Lin H, et al. Assessment of hearing
loss by pure-tone audiometry in patients with mucopolysaccharidoses. Mol
Gen Metab. 2014;111:533–8.
9. Aldenhoven M, Wynn RF, Orchard PJ, O'Meara A, Veys P, Fischer A, et al.
Long-term outcome Hurler syndrome patients after hematopoitic cell
transplantion: an internaitonl muticenter study. Blood. 2015;125(13):2164–72.
10. Wynn RF, Wraith JE, Mercer J, O'Meara A, Tylee K, Thornley M, Church
HJ, Bigger BW. Improved Metabolic Correction in Patients with
Lysosomal Storage Disease Treated with Hematopoitic Stem Cell
Transplant Compare with Enzyme Replacement Therapy. J Pediatr.
2008;154:609–11.
11. Pulshiper MA. Long-term outcomes in MPS-IH: throwing stars. Blood.
2015;125(13):2016–7.
12. Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al.
Enzyme replacement therapy for mucopolysaccharidosis I: a randomized,
double-blinded, placebo-controlled, multinational study of recombinant
human alpha-L-iduronidase (laronidase). J Pediatr. 2004;144(5):581–8.
13. de Ru MH, Boelens JJ, Das AM, Jones SA, van der Lee JH, Mahlaoui N, et al.
Enzyme replacement therapy and/or hematopietic stem cell transplantion
at diagnosis in patietns with mucopolysaccharidosis tyoe I; results of a
European conensus procedure. Orphanet J Rare Dis. 2011;6:55.
14. Gill TM, Feinstein AR. A critical appraisal of the quality of quality of life
measurements. JAMA. 1994;272:619–26.
15. Creswell JW. Qualitative Inquiry & Research Design. Choosing among five
approaches. 2nd ed. Thousand Oaks, CA: Sage; 2007.
16. Charmaz K. Constructing grounded theory. London: Sage; 2006.
17. Papsin BC VA, Bailey CM, Raatcliffe PC, Leighton SEJ. Otologic and
laryngologic manifestation of hte mucopolysaccharidosis after bone marrow
transplanation. Otolaryngol Head Neck Surg. 1998;1998(1):30–6.
18. Yeung AHCM, Horn B, Rosbe KW. Airway Management in children with
mucopolysaccharidosis. Arch Otolaryngol Head Neck Surg. 2009;135(1):73–9.
19. Nashed AA-SS, Gibbons J, MacLusky I, MacFarlane J, Riekstins A, Clarke J,
Narang I. Sleep-related breathing in children with mucopolysaccharidosis.
J Inherit Metab Dis. 2009;32(4):544–50.
20. Pal AR, Langereis EJ, Saif MA, Mercer J, Church HJ, Tylee KL, et al. Sleep
disordered breathing in mucopolysaccharidosis I: a mulitvariant analysis of
patient, therapeutic and metabolic correlators modifying long term clinical
outcome. Orphanet J Rare Dis. 2015;10:42.
21. Lin HYCM, Lin CC, Chen CP, Lin DS, Chuang CK, Niu DM, Chang JH, Lee HC,
Lin SP. Polysomnographic characteristics in patients with
mucopolysaccharidoses. Pediatr Pulmonol. 2010;45(12):1205–12.
22. Weisstein JS, Delgado E, Steinbach LS, Hart K, Packman S. musculoskeletal
manifestations of Hurler syndrome; long-term follow-up after bone marrow
transplant. J Pediatr Orthop. 2004;2004(24):1.
23. LA Clarke WJ, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM,
Berger KI, Sidman M, Kakkis ED, Cox GF. Long-term efficacy and safety of
laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009;
123(1):229–40.
24. Rosen CPT, Larkin E, et al. Healt related quality of life and sleep disordered
breathing in children. Sleep. 2002;25:657–63.
25. Baldassari CMMR, Schubert C, Rudnick EF. Pediatric obstructive sleep
apnea and quality of life: a meta-analysis. Otolaryngol Head Neck Surg.
2008;138(3):265–73.
26. Georgalas C, Tolley N, Kanagalingam J. Measuring quality of life in children
with adenotonsillar disease with the child health questionnaire : a firtst UK
study. Laryngoscope. 2004;114:1849–55.
27. Stewart MGD, Friedman E, et al. Quality of life and sleep study findings after
adenotonsillectomy in children with bstructie sleep apnoea. Arch
Otolaryngol Head Neck Surg. 2005;131:308–14.
28. Chervin RD, Dillon JE, Archbold KH. Conduct problems and symptoms of
sleep disorders in children. J Am Acad Child Adolesc Psychiatry.
2003;42(2):201–8.
29. O'Brien L. The neurocognitive effects of sleep disruption in children and
adolescents. Sleep Med Clin. 2011;6:109–16.
30. Gottleib DJ, Chase C, Vezina RM. Sleep-disordered breathing symptoms are
associted with poorer cognitive funciton in 5-year old children. J Pediatr.
2004;145(4):458–64.
31. Harmatz P, Giugliani R, Schwartz IV, Guffon N, Teles EL, Miranda MC, Wraith
JE, Beck M, Arash L, Scarpa M, Ketteridge D, Hopwood JJ, Plecko B, Steiner
R, Whitley CB, Kaplan P, Yu ZF, Swiedler SJ, Decker C. Mps Vi Study Group.
Long-term follow-up of endurance and safety outcomes during enzyme
replacement therapy for mucopolysaccharidosis VI: Final results of three
clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase.
Mol Genet Metab. 2008;94(4):469–75.
32. Muenzer JB, Eng C, Giugliani R, Harmetz P, Martin R, Ramaswami U, Vellodi
A, et al. Long-term open labeled extension study of idursulfase in the
treatment of Hunter syndrome. Genet Med. 2011;13(2):95–101.
33. Eiser C, Morse R. Can parents rate their child's health-related quality of life?
Results of a systematic review. Qual Life Res. 2001;10(4):347–57.
Soni-Jaiswal et al. Orphanet Journal of Rare Diseases  (2016) 11:96 Page 9 of 9
